Biognosys Announces Appointment of Dr. Patrick Vink as Chairman

The appointment will support a strategic expansion into large-scale proteomics applications across the drug development value chain.

ID: 1558858
recent pressrelease next pressrelease

(PresseBox) - Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today the

Dr. Vink has an M.D. from the University of Leiden and an MBA from the University of Rochester. He brings well as global alliance management. Prior to Cubist, he was Head of the Global Hospital Business and executive team member at Mylan Inc., Head of Global Biopharmaceuticals at Sandoz (a division of Novartis), and held various senior positions at Biogen Inc, Sanofi-Synthelabo, and Numico.

Dr. Vink is currently on the board of several U.S. and European publicly listed and private companies, including as Chairman of F2G and NMD Pharma and Board Member at Amryt Pharma, Santhera Pharmaceuticals and Spero Therapeutics.

As Chairman of Biognosys, Dr. Vink will support the company?s strategic expansion into proteomics for large-scale applications across the drug development value chain.

Dr. Oliver Rinner, CEO of Biognosys, says:-up phase to an established leader in proteomics services and products.?

Dr. Patrick Vink, Chairman of Biognosys, commented:

Biognosys is a leader in next-generation proteomics, dedicated to transforming life science research by making the most advanced proteomics tools available to researchers. The company offers a suite of products and services to decode the proteome and equip researchers from all fields with a deep view of protein expression in cells, tissues, or body fluids. Biognosys? technology is based on high-resolution mass spectrometry, combined with a novel parallel signal processing approach, for unprecedented quantification of large proteomes in a single experiment. More information at: www.biognosys.com



More information:
http://https:// https://



Keywords (optional):



Company information / Profile:

Biognosys is a leader in next-generation proteomics, dedicated to transforming life science research by making the most advanced proteomics tools available to researchers. The company offers a suite of products and services to decode the proteome and equip researchers from all fields with a deep view of protein expression in cells, tissues, or body fluids. Biognosys? technology is based on high-resolution mass spectrometry, combined with a novel parallel signal processing approach, for unprecedented quantification of large proteomes in a single experiment. More information at: www.biognosys.com

PressRelease by

Requests:



PressContact / Agency:



published by: PresseBox
print pressrelease  send to a friend  

Date: 06/17/2020 - 05:00
Language: English
News-ID 1558858
Character count: 6597
Kontakt-Informationen:
Firma: Biognosys AG
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: Schlieren (Zurich)
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 213

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 54


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.